N-alkoxypyrazoles as biomimetics for the alkoxyphenyl group in tamoxifen

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 8, 2003, Pages 1883-1899

  Wenckens, Martin ^a,b   Jakobsen, Palle ^b   Vedsø, Per ^a   Huusfeldt, Per Olaf ^c   Gissel, Birgitte ^b   Barfoed, Marianne ^b   Brockdorff, Bettina Lundin ^d   Lykkesfeldt, Anne E ^d   Begtrup, Mikael ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c Pantheco A/S   (Denmark)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 HYDROXYPYRAZOL 4 YL) 1 PHENYL 2 [4 (2 N,N DIMETHYLAMINOETHYLOXY)PHENYL] 1 BUTENE; 1 (1 HYDROXYPYRAZOL 4 YL) 1 [4 (2 N,N DIMETHYLAMINOETHYLOXY)PHENYL] 2 PHENYL 1 BUTENE; 1 (3 N,N DIMETHYLAMINOPROPYLOXY) 5 ETHYL 4 PHENYLPYRAZOLO[4,3 A]NAPHTHALENE; 1 [1 (3 N,N DIMETHYLAMINOPROPYLOXY)PYRAZOL 4 YL] 1,2 DIPHENYL 1 BUTENE; 1 [1 (3 N,N DIMETHYLAMINOPROPYLOXY)PYRAZOL 4 YL] 2 (2 FLUOROPHENYL) 1 PHENYL 1 BUTENE; 1 [1 (3 N,N DIMETHYLAMINOPROPYLOXY)PYRAZOL 4 YL] 2 (4 METHOXYPHENYL) 1 PHENYL 1 BUTENE; 1 [1 (3 N,N DIMETHYLAMINOPROPYLOXY)PYRAZOL 4 YL] 2 (THIEN 3 YL) 1 PHENYL 1 BUTENE; ESTROGEN RECEPTOR ALPHA; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOMIMETICS; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

LATEOLABRAX JAPONICUS; MINK CELL FOCUS-FORMING VIRUS;

EID: 12244304222     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00566-7     Document Type: Article

References (54)

1. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., Manning D.L., Nicholson R.I. J. Natl. Cancer Inst. 87:1995;746.
2. For a recent review, see: Tonetti D. A.; Jordan, V. C. J. Steroid Biochem. Mol. Biol. 62:1997;119.
3. For a recent review, see: Gradishar W.J., Jordan V.G. J. Clin. Oncol. 15:1997;840.
4. Favoni R.E., Cupis A. TiPS. 19:1998;406.
5. Dehal S.S., Kupfer D. Cancer Res. 57:1997;3402.
6. Ruenitz P.C., Shen Y., Li M., Liang H., Whitehead R.D., Pun S., Wronski T.J. Bone. 23:1998;537.
7. Srikanth N., Tan C.-H., Ng S.-C., Loh T.-P., Koh L.-L., Sim K.-Y. J. Chem. Res. (M). 1997;1828.
8. Schwartz W., Hartmann R.W., Schönenberger H. Arch. Pharm. 324:1991;223.
9. Schwartz W., Hartmann R.W., Schönenberger H. Arch. Pharm. 324:1991;231.
10. Olier-Reuchet C., Aitken D.J., Husson H.-P. Heterocyc. Commun. 1:1998;4.
11. Haroutounian S.A., Scribner A.W., Katzenellenbogen J.A. Steroids. 60:1995;636.
12. Croisy-Delcey M., Croisby A., Carrez D., Huel C., Chiaronic A., Ducrout P., Bisagni E., Jin L., Leclercq G. Bioorg. Med. Chem. 8:2000;2629.
13. Segall A., Pappa H., Casaubon R., Martin G., Bergoc R., Pizzorono M.T. Eur. J. Med. Chem. 1995;165.
14. Top S., Dauer B., Vaissermann J., Jaouen G. J. Organometallic Chem. 541:1997;335.
15. Bérubé G., He Y., Groleau S., Séné A., Thérien H.-M., Caron M. Inorg. Chim. Acta. 262:1997;139.
16. Auger S., Mérand Y., Pelletier J.D., Poirier D., Labrie F. J. Steroid. Biochem. Mol. Biol. 52:1995;547.
17. Magarian R.A., Avor K.S., Overacre L.B., Kunchandy J., Paxton T.R. Anti-Cancer Drug Des. 10:1995;311.
18. Overacre S.B., Magarian R.A. Bioorg. Chem. 26:1998;15.
19. Fink B.E., Mortensen D.S., Stauffer S.R., Aron Z.D., Katzenellenbogen J.A. Chem. Biol. 6:1999;205.
20. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. J. Med. Chem. 2000;4934.
21. Brown S.D., Armstrong R.W. J. Am. Chem. Soc. 118:1996;6331.
22. Brown S.D., Armstrong R.W. J. Org. Chem. 62:1997;7076.
23. Liberman M.E., Gorski J., Jordan V.C. J. Biol. Chem. 258:1983;4741.
24. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engström O., Ohman L., Greene G.L., Gustafsson J.-A., Carlquist M. Nature. 389:1997;753.
25. Jin L., Legros N., Leclercq G., Hardcastle I.R., Jarman M. Cancer Chemo. Pharm. 41:1998;339.
26. Deplassand E.S., Yang D.J., Wallace S., Cherif A., Quadri S.M., Price J., Joubert A., Inoue T., Podoloff D.A. J. Pharm. Sci. 85:1996;553.
27. Magarian R.A., Avor K.S., Overacre L.B., Kunchandy J., Pazton T.R. Anti-Cancer Drug Des. 10:1995;311.
28. The calculations were performed using Hyper Chem™ Release 4 for Windows, Molecular Modeling System.
29. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. Cell. 95:1998;927.
30. Morehouse F.R., Maass O. Can. J. Res. 1933;306.
31. Yamanaka H., Shiraiwa M., Yamamoto E., Sakamoto T. Chem. Pharm. Bull. 29:1981;3543 Ezquerra J., Pedregal C., Lamas C. J. Org. Chem. 61:1996;5804.
32. Yamanaka H., Shiraiwa M., Yamamoto E., Sakamoto T. Chem. Pharm. Bull. 29:1981;3543 Ezquerra J., Pedregal C., Lamas C. J. Org. Chem. 61:1996;5804.
33. Sharma M. Biochem. Biophys. Res. Commun. 273:2000;40.
34. Andersen H.R., Andersson A., Arnold S.F., Autrup H., Barfoed M., Beresford N.A., Bjerregaard P., Christiansen L.B., Gissel B., Hummel R., Bonefeld-Jorgensen E., Korsgaard B., Le-Guevel R., Leffers H., McLachlan V., Moller V., Bo-Nielsen J., Olea N., Oles-Karasko A., Pakdel F., Pedersen K.L., Perez P., Skakkebæk N.E., Sonnenschein C., Soto A.M., Sumpter J.P., Thorpe S.M., Grandjean P. Environ. Health Perspect. 107:1999;89.
35. Thorpe S.M. Breast Cancer Res. Treat. 9:1987;175.
36. Jordan V.C., Gosden B. Mol. Cel. Endocrinol. 27:1982;291.
37. Murphy C.S., Langan-Fahey S.M., McCague R., Jordan V.C. Mol. Pharmacol. 38:1990;737.
38. Lednicher D., Lyster S.C., Aspergren B.D., Duncan G.W. J. Med. Chem. 9:1966;172.
39. Lednicher D., Lyster S.C., Duncan G.W. J. Med. Chem. 10:1967;78.
40. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. Cell. 95:1998;927.
41. Qiu J., Stevenson S.H., O'Beirne M.J., Silverman R.B. J. Med. Chem. 42:1999;329.
42. Shani J., Gazit A., Livshitz T., Biran S. J. Med. Chem. 28:1985;1504.
43. Lykkesfeldt A.E., Larsen S.S., Briand P. Int. J. Cancer. 64:1995;529.
44. Lykkesfeldt A.E., Madsen M.W., Briand P. Cancer Res. 54:1994;1587 Larsen S.S., Madsen M.W., Lensen B.L., Lykkesfeldt A.E. Int. J. Cancer. 72:1997;1129.
45. Lykkesfeldt A.E., Madsen M.W., Briand P. Cancer Res. 54:1994;1587 Larsen S.S., Madsen M.W., Lensen B.L., Lykkesfeldt A.E. Int. J. Cancer. 72:1997;1129.
46. Davois S., White R., Parker M.M.G. J. Cell Sci. 106:1993;1377.
47. Gottardis M.M., Ricchio M.D., Satyaswaroop P.G., Jordan V.C. Cancer Res. 50:1990;3189.
48. Briand P., Lykkesfeldt A.E. Cancer Res. 44:1984;1114.
49. Hegedeus, L. S. In Organometallics in Synthesis; Schlosser, M., Ed., Wiley: New York, 1995; p 448.
50. Suffert J. J. Org. Chem. 54:1989;509.
51. Ishiyama T., Matsuda N., Miyaura N., Suzuki A. J. Am. Chem. Soc. 15:1993;11018.
52. Felding J., Kristensen J., Bjerregaard T., Sander L., Vedsø P., Begtrup M. J. Org. Chem. 64:1999;4196.
53. Picon M., Haller A. Acad. Sci. 1914;1184.
54. Sonogashira, K. In Metal-catalyzed Cross-coupling Reactions; Diederich, F.; Stang, P. J. E., Eds.; Wiley-VCH: 1998.